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Abstract
Ubiquitin conjugation and deconjugation provides a powerful signalling system to change the fate of its
target enzymes. Ubiquitination levels are organized through a balance between ubiquitinating E1, E2
and E3 enzymes and deubiquitination by DUBs (deubiquitinating enzymes). These enzymes are tightly
regulated to control their activity. In the present article, we discuss the different ways in which DUBs of the
USP (ubiquitin-specific protease) family are regulated by internal domains with a UBL (ubiquitin-like) fold.
The UBL domain in USP14 is important for its localization at the proteasome, which enhances catalysis. In
contrast, a UBL domain in USP4 binds to the catalytic domain and competes with ubiquitin binding. In this
process, the UBL domain mimics ubiquitin and partially inhibits catalysis. In USP7, there are five consecutive
UBL domains, of which the last two affect catalytic activity. Surprisingly, they do not act like ubiquitin
and activate catalysis rather than inhibiting it. These C-terminal UBL domains promote a conformational
change that allows ubiquitin binding and organizes the catalytic centre. Thus it seems that UBL domains
have different functions in different USPs. Other proteins can modulate the roles of UBL domains in USP4
and USP7. On one hand, the inhibition of USP4 can be relieved when the UBL is sequestered by another USP.
On the other, the activation of USP7 is increased, when the UBL-activated state is stabilized by allosteric
binding of GMP synthetase. Altogether, UBL domains appear to be able to regulate catalytic activity in USPs,
but they can use widely different mechanisms of action, in which they may, as in USP4, or may not, as in
USP7, use the direct resemblance to ubiquitin.
Introduction
Ubiquitin conjugation is a post-translational modification
where a 76-amino-acid ubiquitin protein is conjugated to a
lysine residue on a target protein. Since ubiquitin itself has
seven lysine residues, this results in a plethora of signals
with roles in different cellular processes [1]. In practice,
ubiquitination is important in just about any cellular event,
from endocytosis to transcription, and from DNA repair to
the cell cycle.
Because of these critical cellular roles, the ubiquitination
event is balanced by deubiquitination. There are five classes
of DUBs (deubiquitinating enzymes) that hydrolyse the
isopeptide bond between ubiquitin and its target [2,3].
The USP (ubiquitin-specific protease) family is the largest
family of DUBs, with approximately 85 members [2].
To control the necessary levels of ubiquitination, DUBs
need to be tightly regulated, and this is organized in a variety
of ways. Such regulation can affect the recruitment to the
target, the specificity to different ubiquitin chain types or
the intrinsic catalysis. It can be organized through post-
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translational modifications, through external modulating
proteins, through the substrate and through internal domains
within the DUB protein [3–6].
Interestingly, several members of the USP family of
DUBs contain UBL (ubiquitin-like) domains. These protein
domains are often found in multidomain proteins. They
share the β-grasp fold with ubiquitin, although they lack the
terminal glycine residues that are required for conjugation
to a target lysine residue. Some UBLs have clear sequence
similarity to ubiquitin and others do not. The latter are
therefore sometimes referred to as UFDs (ubiquitin-fold
domains) (K. Hofmann, personal communication).
So far, several different families of UBL domains have
been described [7]. They are present in proteasomal shuttle
factors such as Rad23 and Dsk2, where they are believed to
play a role in recruitment of ubiquitinated proteins to the
proteasome [8,9]. Integrated UBL domains in other proteins
such as parkin can also be recruited to the proteasome
[10]. Recruitment, in this case to DUB targets, is also
seen as the function of the UBL domain in the USP1
activator UAF1 (USP1-associated factor 1) [11]. However,
UBL domains also play roles in the enzymatic activity of
certain immune-response-inducible kinases, such as IKKβ
(inhibitor of nuclear factor κB kinase β) [12].
The first UBL domain in the USP family was identified
in USP14 by Shi and co-workers [13]. Subsequently, a
bioinformatics analysis revealed that related β-grasp fold
domains exist in at least 16 USPs [14] (Figure 1A). Given their
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Figure 1 USPs contain UBL domains
(A) Several USPs contain one or more UFDs embedded in the sequence at different locations with respect to the catalytic
domain [14]. (B) Three-dimensional structures have been resolved for several UBL domains in USPs, revealing that they
indeed fold like ubiquitin. If more than one structure is known, all PDB identifiers are given, with the first structure shown.
aa, amino acids; TRAF, tumour-necrosis-factor-receptor-associated factor.
low sequence homology with ubiquitin, they really should
be called UFDs. In practice, however, they have been named
UBL domains and we will maintain this nomenclature in the
present article.
Despite the lack of sequence similarity among each other,
they share common features, since, e.g., a PSI-BLAST
analysis of any member of this subfamily will find the
other UBL domains in USPs efficiently, but not the UBL
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Figure 2 UBL domains inhibit USP4, but activate USP7 catalysis
(A) USPs have a common catalytic domain, here shown in cartoon representation for the D1D2 fragment of USP4 (see
Figure 1) [29] (left) and for USP7 in complex with ubiquitin [44] (right). The insert containing the UBL domain of USP4 is
indicated. (B) The UBL domain in USP4 inhibits catalytic activity in ubiquitin–AMC assays, whereas (C) the UBL domains in
USP7 strongly activate catalysis.
domains in unrelated proteins. Several structures of these
UBL domains have been resolved (Figure 1B), and a structural
alignment shows 1–3 Å (1 Å = 0.1 nm) root mean square
deviations.
The USP family of DUBs has a common catalytic domain
(Figure 2A) in which a hand-like domain holds on to
ubiquitin, guiding the ubiquitin C-terminus to the catalytic
triad of the papain-like cysteine protease family. The overall
length of the catalytic domain of the USP family members
varies widely, owing to insertions at five different sites [5].
The UBL domains are inserted at different sites relative
to the catalytic domain (Figure 1A), N-terminally to, inserted
into or C-terminally to the catalytic domain
It was found that these UBL domains can play widely
different roles in the regulation of their DUB activity. In the
present article, we compare the function of the three UBL
domains that have been described, and their widely different
activities in recruitment, inhibition or activation.
USP14: recruitment to the proteasome
USP14 is localized at the proteasome [15], where it plays
a special role in rescuing proteins from degradation by
removing ubiquitin [13,16]. This release of ubiquitin spares
it from degradation, minimizing fluctuations in the free
ubiquitin pool. Loss of USP14 leads to ataxia [17] and reduced
levels of ubiquitin [18].
USP14 has an N-terminal UBL domain (Figure 1B). The
crystal structure of the catalytic domain shows a catalytic
triad correctly folded for catalysis, but a number of blocking
loops that prevent access to the ubiquitin-binding site [13].
Biochemical analysis showed that the UBL domain in USP14
is important for its recruitment to the proteasome [13].
The proteasome interaction is critical for efficient catalysis
by USP14, presumably by rearranging the blocking loops
[13]. The primary role of the UBL domain appears to be in
recruitment to the proteasome, similar to roles described for
UBL domains in Rad23 and parkin [9,10].
USP4: inhibiting catalysis
USP4 was known previously as UNP (ubiquitous nuclear
protein) [19]. Identified as a proto-oncogene related to
Tre2/Tre17 (USP6), USP4 shows a consistently elevated
gene expression level in small cell tumours and lung
adenocarcinomas, suggesting that it may have a causative role
in neoplasia [20]. Besides possible roles in TNFα (tumour
necrosis factor α) [21] and Wnt signalling [22], as well as
C©The Authors Journal compilation C©2012 Biochemical Society
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recruitment to the adenosine A2A receptor [23], USP4 is
recruited to the spliceosome by complex formation with
Sart3 [24]. Here, it preferentially deubiquitinates Lys63-linked
chains on the U4 component Prp3. Another component of
the spliceosome complex is the catalytically inactive USP39
[24], which controls the mRNA levels of Aurora B [25]. More
recently, Zhang et al. [26] have shown how USP4 stabilizes
ARF-BP1 (alternative reading frame-binding protein 1) and
the subsequent reduction in p53 levels [26].
There are two homologues of USP4, namely USP11
and USP15. These USPs have a common domain structure
and high sequence similarity (47–57 % identity), but
very different biological functions. Each of them has an
N-terminal DUSP (domain present in ubiquitin-specific
protease)-UBL domain combination, and several crystal
structures of these have been solved showing differences
mainly in the relative orientation of the DUSP and UBL
domains and in the way the finger loop connecting the two
domains packs against the UBL domain [27,28]. The function
of these DUSP-UBL domains in the full-length protein is not
yet understood but given the significant differences in surface
characteristics between ubiquitin and the UBL domain, it is
unlikely that the USP15 N-terminal UBL domain may act
as ubiquitin. To date, the only functional role of the DUSP-
UBL domain is to mediate the interaction between USP4 and
Sart3 [24].
The catalytic domain of USP4 contains a large insert
into which a UBL domain is embedded in a larger
unstructured region. Removal of this insert by proteolysis
or by mutagenesis results in the canonical USP catalytic
domain (Figure 2A) split into two domains named D1 and
D2 [29] (Figure 1A). Its crystal structure is highly similar to
most other USP catalytic domain structures with a correctly
aligned catalytic centre [29]. As in USP14, rearrangement of
a number of blocking loops is required to allow access
of ubiquitin to the binding site in this catalytic domain.
The role of the UBL domain inserted in the catalytic do-
main became clear upon comparison of the catalytic activity
of the full catalytic domain with that of the D1D2 fragment,
lacking the UBL insert. In these assays, the D1D2 fragment
was much more efficient against a minimal fluorigenic
ubiquitin substrate (Figure 2B) or against di-ubiquitin [29],
indicating that the UBL insert inhibits activity.
Kinetic analysis of the enzymatic activity revealed
differences, primarily at the Km level, suggesting that the
insert acts as a competitive inhibitor. Indeed, binding studies
revealed an affinity of ∼1 μM between the UBL domain and
the D1D2 catalytic domain.
Since the UBL domain binds so well, a strong inhibition of
ubiquitin binding is expected when the insert is present in the
catalytic domain. In practice, however, the difference is not
that extreme. Also the K i for the UBL domain against D1D2,
as determined from a Dixon-type analysis where kinetic
data are measured at different inhibitor concentrations, was
found to be ∼45 μM, substantially higher than the binding
constant. Hence further regulation of inhibition must take
place, possibly through conformational changes.
In USP4, the UBL domain competes with ubiquitin
for its binding site in the USP hand and this inhibits
the catalytic activity. Importantly, the current data do not
answer the question of whether the UBL domain adopts
the same conformation in the USP4-binding site. Since there
is no sequence similarity to ubiquitin, it could bind in any
orientation in the USP4 catalytic site, but in any case it does
compete directly with ubiquitin for this binding site.
USP7: activating catalysis
USP7/HAUSP (herpesvirus-associated ubiquitin-specific
peptidase) has many roles in controlling critical proteins
during the stress response [30]. It was first identified as
a DUB for p53, but later found to also control auto-
ubiquitination, and thus stability, of the E3 ligase of p53,
MDM2 (murine double minute 2). Dependent on external
conditions and regulators such as TSPYL5 (testis-specific Y-
encoded-like protein 5) [31], it can thus either activate or
inactivate p53 function. A number of other important targets
have been resolved, including PTEN (phosphatase and tensin
homologue deleted on chromosome 10) [32] and FOXO4
(forkhead box O4) [33]. In other reports, USP7 was shown to
regulate claspin levels, affecting the DNA-damage checkpoint
[34] and to alter epigenetic responses through regulation
of DNMT1 [DNA (cytosine-5-)-methyltransferase 1] and
PRC1 (Polycomb-repressive complex 1) [35,36]
USP7 is an essential gene [37] and even specific knockout
in brain cells leads to neonatal lethality [38]. USP7 is up-
regulated in prostate cancer [32] and relates directly to tumour
aggressiveness, linking it to an important role in non-small-
cell lung carcinogenesis [39]. In a colon cancer xenograft
model, both up- and down-regulation of USP7/HAUSP
inhibit tumour growth in the absence of stress [40].
Altogether, USP7 is thought to be an attractive target for
cancer therapy [30,41,42].
USP7 consists of an N-terminal TRAF (tumour-necrosis-
factor-receptor-associated factor) domain that is important
for recruitment to the target proteins [13,43]. It also has a
minimal catalytic domain, that was shown to adopt an inactive
state, where the catalytic triad is misaligned [44]. However,
in the presence of covalently bound ubiquitin, this site is
reorganized to the active triad as found in other USPs, such
as USP14 and USP4 [44]. Interestingly, USP7 has a 64 kDa
C-terminal domain that contains five UBL domains. This
domain has been named the HUBL domain (for HAUSP
UBL domain) [45].
Analysis of the USP7 function showed that the C-terminal
HUBL domain is required for full activity of the enzyme
[45–47]. The crystal structure of this domain revealed that
the five UBL domains are arranged in an extended 2 + 1 + 2
fold, where the dimers share a distinct hydrophobic core [45].
SAXS (small-angle X-ray scattering) analysis showed that
despite some flexibility, the extended state occurs in solution,
but, in the full-length protein, the HUBL domain folds back
on to the catalytic domain.
C©The Authors Journal compilation C©2012 Biochemical Society
Biochemical Society Annual Symposium No. 79: Frontiers in Biological Catalysis 543
Figure 3 Model for UBL domain function in USP catalysis and modulation by external regulators
(A) USP4 is inhibited by its UBL domain: it competes with ubiquitin for binding to the active site. This can be relieved by other
USPs binding to the inhibitory UBL domain [29]. (B) USP7 is activated by its UBL domains. Binding of the C-terminal peptide
and last two UBL domains, HUBL45, promotes ubiquitin binding and rearrangement of the catalytic triad into its active state.
This active state, with HUBL45 bound, is allosterically promoted by GMPS binding to the first three UBL domains, HUBL123
[45].
How the HUBL domain activates USP7 was studied
in detail [45]. Mapping studies showed that the two C-
terminal UBL domains are sufficient for full activation of
the catalytic domain. The very C-terminal peptide after the
last UBL is necessary, but not sufficient, for this activation,
and it requires the HUBL-45 di-UBL unit for binding
to the catalytic domain. This binding promotes ubiquitin
binding, improving it from virtually undetectable to 1 μM
affinity. It also improves catalysis, presumably by helping to
rearrange the catalytic triad, through interaction with a so-
called ‘switching’ loop close to the active site [45].
Point mutants in the switching loop (at Trp285 and
Glu286) as well as in the C-terminal peptide (most notably
Ile1100) interfere with the activation of the catalytic site and
prevent high-affinity ubiquitin binding. Interestingly, USP7
overexpression in cells is capable of stabilizing both MDM2
and p53, but these mutations completely abrogate that ability,
showing that the activation is critical for proper functioning
in cells [45].
Thus the UBL domains in USP7 function to activate the
catalytic domain. They bind to the catalytic domain at a
site different from ubiquitin and promote ubiquitin binding,
rather than interfering with it. Therefore the activation is
UBL-dependent, but not by mimicking ubiquitin function.
Modulation of UBL function
Interestingly, the regulatory roles of UBL domains in both
USP4 and USP7 can be modulated further by other proteins.
Two examples have been identified (Figure 3), but others may
yet be found.
In the spliceosomal Prp19 complex, a second USP, USP39,
is found besides USP4 itself [24]. This unusual DUB lacks the
catalytic residues and therefore cannot cleave ubiquitin from
any target [25], but it does have the conserved ubiquitin-
binding site. Interestingly, it also has kept the ability to bind
the USP4 internal UBL domain, with similar affinity. When
USP39 is added to the USP4 catalytic domain, it can provide
a partial relief of USP4 ubiquitin-binding inhibition by the
internal UBL domain [29]. So far this has only been analysed
in vitro and obviously this mechanism needs to be studied in
the context of the spliceosome. Moreover, it is possible that
other USPs play a similar modulating role, thus requiring
further studies.
The USP7 protein is in a dynamic equilibrium, between
the activated and the inactive state. This is seen in the SAXS
analysis and it could be confirmed by analysis of the effect of
the modulating protein GMPS (GMP synthetase) [45].
GMPS is a metabolic enzyme that is important for the
synthesis of GMP. However, part of GMPS in cells is found
in a complex with USP7 [48–50]. It is capable of activating
USP7 against various targets, including p53, and it is essential
for the activity of USP7 against histone H2B [48–50]. Thus
GMPS clearly has roles in determining target specificity.
However, it could be shown that GMPS also activates
USP7 against a minimal target, such as ubiquitin–AMC (7-
amino-4-methylcoumarin). It binds to HUBL123 with high
affinity and it does not interact with either the catalytic or
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the HUBL45 domains. Nevertheless, its ability to activate
USP7 requires the proper activation through the HUBL45
domain interaction with the switching loop, since neither
USP7 lacking the activating HUBL45 nor USP7 with point
mutants in the switching loop or activation peptide can
be activated by GMPS. This suggested that GMPS would
activate USP7 by shifting the equilibrium between the active
and the inactive state. In that case, it should stimulate the
interaction between the catalytic domain and the HUBL45
region. Indeed, binding studies showed that addition of
GMPS could shift the equilibrium between the catalytic
domain and the complete HUBL domain from 50 μM to
2 μM, whereas the HUBL123 does not bind at all under
these conditions, indicating that GMPS indeed allosterically
stabilizes the activated state.
In this manner, regulatory proteins can change the effect of
the UBL-dependent inhibition (USP4) or activation (USP7).
It seems likely that other modulators of these functions may
exist. In particular, the HUBL domain in USP7 would be
a prime target for inactivation, since the equilibrium could
provide an excellent manner to (temporarily) attenuate the
function of this important DUB.
Future perspectives
Currently, we are starting to gain information about
regulatory roles for UBL domains in USP function at the
biochemical level. For USP7, the importance of the activation
by the C-terminal HUBL domain has been validated in
cells, as it was shown that overexpressed USP7 variants
with mutations in the switching loop or C-terminal peptide
lost the ability to stabilize p53 or MDM2 in cells. In contrast,
the recruitment and inhibitory roles of the UBL domains in
USP14 and USP4 needs validation.
For most UBL domains in USPs, we do not yet know
their function. It will therefore be interesting to see whether
these UBL-containing USPs are regulated in similar ways and
what, e.g., the effect of the N-terminal UBL domain on USP4
may be. One would imagine that USP11 and USP15 show
similar regulatory mechanisms since they are closely related
paralogues, despite differences in N-terminal domains and
cellular functions.
One interesting question will be whether the localization
with respect to the active site is relevant for the regulatory role
of the UBL domain. If that is the case, the current studies on
USP14, USP4 and USP7 might be predictive for UBL roles
in other USPs. Future studies will be required to address this
question.
It seems likely that any UBL domain in a USP is subject to
further regulation from external modulators, such as has been
described in the present article for the proteasome, USP39 and
GMPS. One could also envisage possible other modulators
which could, e.g., stabilize the inactive state for USP7 or the
inhibited state for USP4. Many different interactors of USPs
are known [51] and some may well have such functions.
An interesting variation on regulation of USPs by UBL
domain is that by UAF1. This regulator of USP1, USP12 and
USP46 contains two domains with a ubiquitin or SUMO-like
fold. One of these domains is involved in the recruitment to
targets [28]. The domain is not a member of the USP family of
UBL domains, but it illustrates that further UBL domains can
be involved in their regulation and suggests a fourth possible
role of these UBL domains.
Finally, it would be of interest to decipher why such similar
modules have evolved to these highly different functions and
to which extent the ubiquitin scaffold is relevant to their
function. Are there any rules at the sequence level or could
one predict a function from the location in the USP? These
are questions for future research.
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